CD138-CAR-T cells

CD138-CAR-T cells are an investigational chimeric antigen receptor (CAR) T-cell therapy designed to target CD138 (syndecan-1), a cell surface proteoglycan highly expressed on malignant plasma cells in multiple myeloma. Developed by various academic and clinical institutions, including He'nan Provincial People's Hospital, Chinese PLA General Hospital, and Soochow University, these autologous or donor-derived T cells are genetically engineered to express a CAR construct containing an anti-CD138 single-chain variable fragment (scFv) coupled with costimulatory domains (such as 4-1BB/CD137 or CD28) and the CD3ζ signaling domain. Upon infusion, the CAR-T cells selectively bind to CD138-expressing myeloma cells, triggering T-cell activation, expansion, and targeted cytotoxicity. CD138-CAR-T cell therapy is primarily being evaluated in clinical trials for the treatment of relapsed or refractory multiple myeloma, both as a monotherapy and in sequential or combination regimens with other CAR-T therapies (such as BCMA-targeted CAR-T cells).

Other names

CART-138CART138CART 138CD138 CAR-TCD-138 CAR-TCD 138 CAR-TCD138 CAR-T cellsCD-138 CAR-T cellsCD 138 CAR-T cellsCD138-directed CAR-T cellsCD-138-directed CAR-T cellsCD 138-directed CAR-T cellsCD138-targeted CAR-T cellsCD-138-targeted CAR-T cellsCD 138-targeted CAR-T cellsCD138CAR-CD137/TCRzeta-expressing T lymphocytesanti-CD138 CAR T cellsanti-CD-138 CAR T cellsanti-CD 138 CAR T cellsanti-CD138 CAR-T cellsanti-CD-138 CAR-T cellsanti-CD 138 CAR-T cellschimeric antigen receptor T cells with specificity for CD138